Summary
Prolonged pretreatment of rats with the atypical antidepressant rolipram attenuates noradrenaline (NA) sensitivity of the cerebral cortical cAMP generating system. The development of this down-regulation is time (7 d treatment required) and dose dependent (EC50=0.35 mg/kg). Density ofβ-adrenoceptor as measured by (−)-3H-dihydroalprenolol [(−)-3H-DHA] binding is also reduced by rolipram pretreatment. The effect of rolipram is absolutely stereospecific for the (−)-enantiomer (ED50=0.18 mg/kg). In addition, only with this isomer, a reduction in daily weight gain was found compared to sham treated controls. Presynaptic denervation using intracerebroventricular (i.c.v.) injections of 6-hydroxydopamine (6-OHDA) prior to or during rolipram treatment did not completely block the effect of a rolipram treatment on down-regulation of cerebral corticalβ-adrenoceptors. The data favor a prea- and postsynaptic action of rolipram different from all other antidepressants studied so far in this experimental setting.
Rolipram is known as inhibitor of brain phosphodiesterase. Using partially purified calmodulin-independent phosphodiesterase from brain it is shown that exclusively the (−)-enantiomer of rolipram inhibits phosphodiesterase with an IC50 of 1.25 μmol/l whereas the (+)-isomer possesses little potency. Since a marked stereospecificity for the (−)-isomer of rolipram was displayed in all pharmacological parameters tested so far with (+)- and (−)-rolipram, it is suggested that stereospecific and isozyme specific inhibition of cAMP-phosphodiesterase is, at least in part, related to the mechanism of action of the potential antidepressant drug rolipram and possibly of other antidepressants as well.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexander RW, Davis JN, Lefkowitz RJ (1975) Direct identification and characterization ofβ-adrenergic receptors in rat brain. Nature (Lond) 258:437–440
Berndt S, Schwabe U (1973) Effect of psychotropic drugs on phosphodiesterase and cyclic AMP level in rat brain in vivo. Brain Res 63:303–312
Bevan P, Bradshaw CM, Szabadi E (1975a) Effect of iprindole on responses of single cortical and caudate neurons to monoamines and acetylcholine. Br J Pharmacol 55:17–25
Bevan P, Bradshaw CM, Szabadi E (1975b) Effects of desipramine on neuronal responses to dopamine, noradrenaline, 5-hydroxytryptamine and acetylcholine in the caudate nucleus of the rat. Br J Pharmacol 54:285–293
Bradshaw CM, Roberts MHT, Szabadi E (1974) Effects of imipramine and desipramine on responses of single neurons to noradrenaline and 5-hydroxytryptamine. Br J Pharmacol 52:349–358
Bylund DB, Snyder SH (1976) Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12:568–580
Davis CW (1984) Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochim Biophys Acta 797:354–362
Gilman AG (1970) Protein binding assay for adenosine 3′, 5′-cyclic adenosine monophosphate. Proc Natl Acad Sci USA 67:305–312
Harden TK, Wolfe BB, Sporn JR, Poulos BK, Molinoff PB (1977) Effects of 6-hydroxydopamine on the development of the beta adrenergic receptor/adenylate cyclase system in rat cerebral cortex. J Pharmacol Exp Ther 203:132–143
Horowski R, Sastre-Y-Hernandez M (1985) Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Current Therapeutic Res 38:23–29
Huang M, Ho AKS, Daly JW (1973) Accumulation of adenosine cyclic 3′, 5′-monophosphate in rat cerebral cortical slices. Stimulatory effect of alpha and beta adrenergic agents after treatment with 6-hydroxydopamine, 2,3,5-trihydroxyphenethylamine, and dihydroxytryptamines. Mol Pharmacol 9:711–717
Jones RSG, Roberts MHT (1979a) Potentiation of responses to monoamines by antidepressants after destruction of monoamine afferents. Brit J Pharmacol 65:501–510
Jones RSG, Roberts MHT (1979b) Potentiation of responses of cortical neurones to 3′, 5′-cyclic adenosine monophosphate by desipramine. Neuropharmacology 18:701–704
Kalisker A, Rutledge CO, Perkins JP (1973) Effect of nerve degeneration by 6-hydroxydopamine on catecholamine-stimulated adenosine 3′5′-monophosphate formation in rat cerebral cortex. Mol Pharmacol 9:619–629
Kincaid RL, Manganiello VC, Odya CE, Osborne JC, Stith-Coleman IE, Danello MA, Vaughan M (1984) Purification and properties of calmodulin-stimulated phosphodiesterase from mammalian brain. J Biol Chem 259:5158–5166
Kopanski C, Türck M, Schultz JE (1983) Effects of long-term treatment of rats with antidepressants on adrenergic receptor sensitivity in cerebral cortex: structure activity study. Neurochemistry International 5:649–659
Mishra R, Janowsky A, Sulser F (1980) Action of mianserin and zimelidine on the norepinephrine receptor-coupled adenylate cyclase system in brain: subsensitivity without reduction inβ-adrenergic receptor binding. Neuropharmacology 19:983–987
Pearson ES, Hartley HO (1976) Biometrica tables for statisticians vol I, Table 29. Cambridge Univ Press, Cambridge
Perkins JP, Moore MM (1973) Characterization of the adrenergic receptors mediating a rise in cyclic 3′, 5′-adenosine monophosphate in rat cerebral cortex. J Pharmacol Exp Ther 185:371–378
Pöch G (1971) Assay of phosphodiesterase with radioactively labeled cyclic 3′-5′-AMP as substrate. Naunyn-Schmiedeberg's Arch Pharmacol 268:272–299
Przegalinski E, Bigajska K, Lewandowska A (1981) The influence of rolipram on the central serotoninergic system. Pharmacopsychiatry 14:162–166
Salomon Y, Londos C, Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541–548
Schmidt BH, Schultz JE (1985) Chronic thyroxine treatment of rats down-regulates the noradrenergic cyclic AMP generating system in cerebral cortex. J Pharmacol Exp Ther 233:466–472
Schneider HH (1984) Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem Pharmacol 33:1690–1693
Schultz JE, Daly JW (1973a) Cyclic adenosine 3′, 5′-monophosphate in guinea pig cerebral cortical slices. I. Formation of cyclic adenosine 3′, 5′-monophosphate from endogenous and from radioactive adenosine triphosphate formed during a prior incubation with radioactive adenine. J Biol Chem 248:843–852
Schultz JE, Daly JW (1973b) Adenosine 3′, 5′-monophosphate in cerebral cortical slices from rat and mouse: stimulatory effect of alpha- and beta-adrenergic agents and adenosine. J Neurochem 21:573–579
Schultz JE, Kopanski C (1985) Effects of lithium and anti-depressants on electrophysiological and biochemical processes in CNS. Acta Pharmacol Toxicol 56 suppl I 43–54
Schultz JE, Siggins GR, Schocker FW, Türck M, Bloom FE (1981) Effects of prolonged treatment with lithium and tricyclic anti-depressants on discharge frequency, norepinephrine responses and beta receptor binding in rat cerebellum: electrophysiological and biochemical comparison. J Pharmacol Exp Ther 216:28–38
Schwabe U, Miyake M, Ohga Y, Daly JW (1976) 4-(3-cyclo-pentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′, 5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12:900–910
Schweitzer JW, Schwartz R, Friedhoff AJ (1979) Intact presynaptic terminals required for beta-adrenergic receptor regulation by desipramine. J Neurochem 33:377–379
Sheppard H, Wiggan G (1971) Analogues of 4-(3,4-dimethoxybenzyl)-2-imidazolidinone as potent inhibitors of rat erythrocyte adenosine cyclic 3′, 5′-phosphate phosphodiesterase. Mol Pharmacol 7:111–115
Sulser F, Vetulani J, Mobley PL (1978) Mode of action of anti-depressant drugs. Biochem Pharmacol 27:257–261
Teshima Y, Kakiuchi S (1974) Mechanism of stimulation of Ca2+ plus Mg2+-dependent phosphodiesterase from rat cerebral cortex by the modulator protein and Ca2+. Biochem Biophys Res Comm 56:489–495
Türck M, Schocker WF, Fathy AM, Schultz JE (1980) Adrenergic subsensitivity of a cell-free adenylate cyclase from rat brain after chronic imipramine treatment. Arch Pharmacy 313:768–773
Vetulani J, Stawarz RJ, Sulser F (1976) Adaptive mechanisms of the noradrenergic cyclic AMP generating system in the limbic forebrain of the rat: adaptation to persistent changes in the availability of norepinephrine. J Neurochem 27:661–666
Wachtel H (1979) Rolipram — A compilation of the animal experimental pharmacodynamics, pharmacokinetics, and toxicology and of the pharmacokinetics and tolerance in the human. Product information for clinical investigators. Schering Research Report
Wachtel H (1982) Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′, 5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 77:309–316
Wachtel H (1983a) Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′, 5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22:267–273
Wachtel H (1983b) Neurotropic effects of the optical isomers of the selective adenosine 3′, 5′-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol 35:440–444
Wachtel H, Schneider HH (1985) The antidepressant activity of rolipram does not depend on presynaptic release of monoamines. Naunyn-Schmiedeberg's Arch Pharmacol 329:R367
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schultz, J.E., Schmidt, B.H. Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causesβ-adrenoceptor subsensitivity in rat cerebral cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 333, 23–30 (1986). https://doi.org/10.1007/BF00569655
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00569655